PAX Financial Group’s West Pharmaceutical WST Stock Holding History

PAX Financial Group’s Portfolio WST Stock Details WST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-1,671	Closed	-$627K	–	252
2023 Q3	$627K	Buy	+1,671	New	+$646K	0.14%	129

Other funds holding WST

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

APG Asset Management Amsterdam, Netherlands $31.6B AUM 19.33% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PAX Financial Group's WST Position: Q4 2023 in Review

PAX Financial Group sold out of West Pharmaceutical (WST) in Q4 2023, closing a stake of 1,671 shares — an estimated $627K sold.

PAX Financial Group first reported a position in WST in Q3 2023 and held it in 1 quarter. The position peaked at $627K in Q3 2023. 782 funds tracked by Wall St. Rank hold WST as of Q4 2023.

PAX Financial Group reported no remaining West Pharmaceutical position as of Q4 2023 after selling out during the quarter.
PAX Financial Group sold 1,671 West Pharmaceutical shares in Q4 2023, an estimated $627K.
PAX Financial Group first reported a position in West Pharmaceutical in Q3 2023 and held it in 1 quarter.
PAX Financial Group's West Pharmaceutical position peaked at $627K in Q3 2023.
782 funds tracked by Wall St. Rank held West Pharmaceutical as of Q4 2023.

Based on PAX Financial Group's 13F filing for Q4 2023, filed 12 Feb 2024.